Notícias e Atividades da Aptevo Therapeutics

Veja o organograma con seus 14 executivos principais

Biografias mais buscadas da Aptevo Therapeutics

• Jeff Lamothe, Chief Executive Officer and Director
• Marvin White, Executive Chairman of the Board
• Barbara Lopez Kunz, Director

Recentes movimentos de executivos em Aptevo Therapeutics

• Mary Janatpour, ingressou na Companhia como Senior Vice President and Chief Scientific Officer  (Notícia publicada em 28 de maio de 2026).
• Marvin White antes Director, President and Chief Executive Officer, agora é Executive Chairman of the Board  (Notícia publicada em 3 de fevereiro de 2026).
• John Niederhuber antes Chairman of the Board, agora é Lead Independent Director  (Notícia publicada em 3 de fevereiro de 2026).

Clique aqui para ver outras movimentos em Aptevo Therapeutics

Criar um alerta
para seguir os movimentos de executivos da Aptevo Therapeutics.

Aptevo Therapeutics possui 2.406 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Aptevo Therapeutics

• Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia | Aptevo Therapeutics Inc
• Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights | Aptevo Therapeutics Inc
• APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting | Aptevo Therapeutics Inc
• Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia | Aptevo Therapeutics Inc
• Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update | Aptevo Therapeutics Inc
• Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update | Aptevo Therapeutics Inc
• Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022 | Aptevo Therapeutics Inc
• Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial | Aptevo Therapeutics Inc
• Aptevo Therapeutics Reports Second Quarter 2020 Financial Results | Aptevo Therapeutics Inc
• Aptevo Therapeutics Secures $25 Million Non-Dilutive Financing from Midcap Financial Trust | Aptevo Therapeutics Inc
• View more press releases Close

Redes sociais sobre Aptevo Therapeutics

• Aptevo Therapeutics na Wikipedia, Google News e Yahoo Finance
• Aptevo Therapeutics na LinkedIn, X (Twitter) e YouTube